Non-GAAP earnings per share of $0.29 in Q2 FY2025 beat expectations, but GAAP revenue missed estimates and GAAP net sales declined 4.0% from the prior year. Management lowered its FY2025 outlook, now ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $23.62, ...

Kenvue, facing investor pressure and lackluster performance in its skin health and beauty unit, has cut its annual sales ...

Recent health news highlights include Kenvue cutting its sales forecast amid strategic changes, Eli Lilly raising its profit ...

The headline numbers for Kenvue (KVUE) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates ...

A rally in stocks sputtered near all-time highs, while Treasuries fluctuated before a $25 billion sale of 30-year bonds that ...

Kenvue (KVUE) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.32 per share a year ago. These figures are ...

The Summit, N.J., drugmaker said Monday that both net and organic sales are likely to be down by low single-digit percentages from last year. It previously guided for net sales to grow 1% to 3%, and ...

(NYSE: KVUE) today announced financial results for the second quarter ended June 29, 2025. "Kenvue has a strong portfolio of ...

Yacktman Asset Management's Q2 2025 13F portfolio value dipped slightly to $7.44B. Click here to read more about the ...

Our thorough analysis encompassing growth, profitability, financial stability, and valuation metrics uncovers fundamental ...

Kenvue says that CEO Thibaut Mongon is departing as the maker of Listerine and Band-Aid brands continues with a strategic review of the company. Kenvue used to be a part ...